|
Anesiva Inc: Premium Company ProfilePublished by: Datamonitor Published: Apr. 22, 2008 - 49 Pages Table of Contents
AbstractIntroductionAnesiva (previously Corgentech), based in South San Francisco, California, is a late stage biotechnology company with two product candidates: Zingo and Altea for the potential treatment of various pain management indications. The company merged with AlgoRX, a privately-held pain management company, to expand its pipeline portfolio. Scope Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies Highlights Anesiva is focused on developing and commercializing novel treatments for pain management. It is preparing to launch Zingo, its approved product, through its sales force and co-promoter in the US. Altea, its second product candidate in Phase II, is being studied for the treatment of post surgery pain management. Anesiva recognized revenues as collaboration payments and license fees from Bristol Meyers Squibb and Lumen Therapeutics. Its total revenues declined from $0.15 million in 2002 to $0.09 million in 2006. Moreover, it did not record revenues in 2004 and 2005. Anesiva expects to generate all of its revenues during 2006-2010 from sales of Zingo. The product is forecasted to contribute $114 million by 2010 to the company’s coffers. Reasons to Purchase Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization . Please note: This is delivered as a Zip file. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||